The purpose of this observational study is to describe patient and disease characteristics as well as treatment patterns in Chinese patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC). In addition, this study characterizes the clinical outcomes for various populations of patients defined by clinical and tumor characteristics, treatment patterns, and hospital category defined by city tier and geographic region.
Study Type
OBSERVATIONAL
Enrollment
1,378
No intervention administered in this study
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, China
the First Hospital of Jilin University
Changchun, China
Sichuan Provincial Cancer Hospital
Chengdu, China
Third Affiliated Hospital of Third Military Medical University
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The First Affiliate Hospital of Guangxi Medical University
Nanning, China
Zhongshan Hospital Fudan University
Shanghai, China
Shanghai First People's Hospital
Shanghai, China
Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
Wuhan, China
...and 1 more locations
Demographic and Socio-Behavioral Characteristics
Time frame: At enrollment
Medical History Characteristics
Time frame: At enrollment
Score Tumor Characteristics Based on Tumor Histology, Stage, Grade, and Lung Cancer Molecular Profile
Time frame: At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years
Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status
Time frame: At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years
Treatment Patterns of First-Line and Subsequent Treatments
Time frame: At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years
Progression-Free Survival (PFS)
Time frame: From enrollment to end of study up to 1.5 years
Overall Survival (OS)
Time frame: From enrollment to end of study up to 1.5 years
Score Health Economic Status Based on Household Income, Diagnosis and Treatment Costs, and Insurance Coverage
Time frame: At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years
Percentage of Serious Adverse Events (SAEs)
Time frame: From enrollment to end of study up to 1.5 years
Percentage of Adverse Events (AEs)
Time frame: From enrollment to end of study up to 1.5 years
Percentage of Non-Serious AEs of Special Interest (AESIs)
Time frame: From enrollment to end of study up to 1.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.